1. |
Du Y, Lin J, Shen J, et al. Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015. BMC Pharmacol Toxicol, 2019, 20(1): 7.
|
2. |
Chen B, Choi H, Hirsch LJ, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav, 2017, 76: 24-31.
|
3. |
Du YR, Lin JH, Mei PN, et al. Analysis of risk factors for antiepileptic drug-induced adverse psychotropic effects in Chinese outpatients with epilepsy. J Clin Neurosci, 2019, 63: 37-42.
|
4. |
Weintraub D, Buchsbaum R, Resor SR Jr, et al. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav, 2007, 10(1): 105-110.
|
5. |
Wood H. Epilepsy: psychiatric adverse effects of levetiracetam linked to genetic variation in dopamine signalling. Nat Rev Neurol, 2012, 8(10): 532.
|
6. |
Jalihal V, Shankar R, Henley W, et al. Eslicarbazepine acetate as a replacement for levetiracetam in people with epilepsy developing behavioral adverse events. Epilepsy Behav, 2018, 80: 365-369.
|
7. |
Rocamora R, Ley M, Molins A, et al. Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: a prospective multicenter study. Epilepsy Behav, 2018, 79: 87-92.
|
8. |
Galanti M, Newport DJ, Pennell PB, et al. Postpartum depression in women with epilepsy: influence of antiepileptic drugs in a prospective study. Epilepsy Behav, 2009, 16(3): 426-430.
|
9. |
Dussaule C, Bouilleret V. Psychiatric effects of antiepileptic drugs in adults. Geriatr Psychol Neuropsychiatr Vieil, 2018, 16(2): 181-188.
|
10. |
Robertson MM, Trimble MR. Depressive illness in patients with epilepsy: a review. Epilepsia, 1983, 24(Suppl 2): S109-116.
|
11. |
Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol, 2016, 12(2): 106-116.
|
12. |
Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf, 2007, 30(7): 555-567.
|
13. |
Brodie MJ, Besag F, Ettinger AB, et al. Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev, 2016, 68(3): 563-602.
|
14. |
Kwon OY, Park SP. Depression and anxiety in people with epilepsy. J Clin Neurol, 2014, 10(3): 175-188.
|
15. |
Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav, 2013, 26(3): 440-449.
|
16. |
Stephen LJ, Wishart A, Brodie MJ. Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. Epilepsy Behav, 2017, 71(Pt A): 73-78.
|
17. |
Mula M. Epilepsy and psychiatric comorbidities: drug selection. Curr Treat Options Neurol, 2017, 19(12): 44.
|
18. |
Chen B, Choi H, Hirsch LJ, et al. Cross-sensitivity of psychiatric and behavioral side effects with antiepileptic drug use. Seizure, 2018, 62: 38-42.
|
19. |
Alfaro A, Asensio M, García-Escrivá A, et al. LAM study: effects of lacosamide on behaviour and quality of life in patients with epilepsy. Neurologia, 2019, 34(1): 1-6.
|
20. |
Schmitz B, Dimova S, Zhang Y, et al. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: post hoc analysis of a prospective, randomized, double-blind trial. Epilepsy Res, 2020, 159: 106220.
|
21. |
Zhu LN, Chen D, Xu D, et al. Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: An indirect comparison. Seizure, 2017, 51: 121-132.
|
22. |
White JR, Walczak TS, Marino SE, et al. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology, 2010, 75(6): 513-518.
|
23. |
Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia, 2015, 56(3): 450-459.
|
24. |
Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia, 2014, 55(Suppl 1): 13-15.
|
25. |
Silberstein SD. Preventive migraine treatment. Neurol Clin, 2009, 27(2): 429-443.
|
26. |
Hesdorffer DC, Ishihara L, Mynepalli L, et al. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol, 2012, 72(2): 184-191.
|
27. |
Kim HJ, Jeon JY, Kim HW, et al. Comparison between the Neurological Disorders Depression Inventory for Epilepsy and the Patient Health Questionnaire-9 in patients with epilepsy according to antiepileptic drug load. Seizure, 2020, 74: 14-19.
|
28. |
Tong X, An D, Lan L, et al. Validation of the Chinese version of the Neurological Disorders Depression Inventory for Epilepsy (C-NDDI-E) in West China. Epilepsy Behav, 2015, 47: 6-10.
|
29. |
Fiest KM, Patten SB, Jetté N. Screening for depression and anxiety in epilepsy. Neurol Clin, 2016, 34(2): 351-361.
|
30. |
Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med, 2007, 167(12): 1240-1245.
|
31. |
Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia, 2003, 44(5): 659-663.
|
32. |
Mula M, Hesdorffer DC, Trimble M, et al. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia, 2009, 50(5): 1072-1076.
|
33. |
Henning OJ, Nakken KO. Psychiatric comorbidity and use of psychotropic drugs in epilepsy patients. Acta Neurol Scand Suppl, 2010, (190): 18-22.
|
34. |
Hamid H, Kanner AM. Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs? Epilepsy Behav, 2013, 26(3): 261-265.
|
35. |
Thomé-Souza MS, Kuczynski E, Valente KD. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy Behav, 2007, 10(3): 417-425.
|
36. |
Specchio LM, Iudice A, Specchio N, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol, 2004, 27(3): 133-136.
|
37. |
伍文清, 肖玉莲, 陈葵. 盐酸帕罗西汀治疗癫痫并发抑郁的临床研究. 中国康复理论与实践, 2012, 18(2): 169-171.
|
38. |
王颖, 孙美珍. 5-羟色胺1A 受体激动剂枸橼酸坦度螺酮对癫痫后抑郁与焦虑的疗效研究. 中华脑科疾病与康复杂志(电子版), 2014, 4(2): 12-15.
|
39. |
Michaelis R, Tang V, Wagner JL, et al. Psychological treatments for people with epilepsy. Cochrane Database Syst Rev, 2017, 10: CD012081.
|
40. |
Mula M. The pharmacological management of psychiatric comorbidities in patients with epilepsy. Pharmacol Res, 2016, 107: 147-153.
|
41. |
Judge BS, Rentmeester LL. Antidepressant overdose-induced seizures. Psychiatr Clin North Am, 2013, 36(2): 245-260.
|
42. |
Alper K, Schwartz KA, Kolts RL, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry, 2007, 62(4): 345-354.
|
43. |
Devinsky O, Pacia SV. Seizures during clozapine therapy. J Clin Psychiatry, 1994, 55(Suppl B): 153-156.
|
44. |
Cock HR. Drug-induced status epilepticus. Epilepsy Behav, 2015, 49: 76-82.
|